Main Article Content
The aim of the study — clinical and metabolic rationale for the selection of the third hypoglycemic agent to enhance the effectiveness of treatment in patients with diabetes mellitus (DM) type 2, assessment of the impact of the therapy intensification due to the addition of voglibose on carbohydrate metabolism parameters, which have not reached target levels during the combination therapy with metformin and glimepiride. Materials and methods. We observed 45 patients with DM type 2, who have not reached the targets of carbohydrate metabolism under the influence of previous treatments (metformin and glimepiride). After the initial clinical examination, patients were divided into two groups. In the first group (n = 30), wе added to the treatment the drug voglibose (Voxid, production of Kusum Pharm Ltd, Ukraine) 0.2 mg before breakfast, lunch and dinner for 12 weeks. Results. After 12 weeks of treatment, the level of glycated hemoglobin (НbА1с) in the first group decreased by 1.5 [1.1; 1.9] % (p < 0.05), in the second group — by 0.1 [0.09; 0.6] % (p > 0.05). 80 % of patients achieved target levels of glycemia. The first group of patients showed a significant increase in HOMA-β index by 24.9 %, as well as a reduction of insulin resistance (HOMA-IR) by 31.5 %. After 12 weeks of therapy, there was a statistically significant decrease in body weight by 2.1 kg in the first group of patients and no response in patients of the second group. Safety has been proveв in terms of the functional state of the liver and kidneys in this therapy. Conclusions. Adding voglibose for intensification of therapy in patients with type 2 DM, who had previously received metformin and glimepiride, has led to a significant improvement in carbohydrate metabolism (decrease in HbA1c by 1.5 %). Better control of carbohydrate metabolism during the combination therapy with metformin, glimepiride, and voglibose is accompanied by an increase of functional activity of pancreatic β-cells, a decrease in insulin resistance in the background of weight loss.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
American Diabetes Association Standards of Medical Care in Diabetes // Diabetes Care. — 2016. — Vol. 39 (Suppl. 1). — S4-S5. doi: 10.2337/dc16-S003.
Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) // Diabetes Care. — 2012. — Vol. 35(6). — P. 1364-1379.
Kharroubi A.T., Darwish H.M. Diabetes mellitus: The epidemic of the century // World J. Diabetes. — 2015. — Vol. 25(6). — P. 850-867. doi:10.4239/wjd.v6.i6.850.
Simmons R.K., Echouffo-Tcheugui J.B., Sharp S.J. et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial // The Lancet. — 2012. — Vol. 380(9855). — P. 1741-1748. doi: 10.1016/s0140-6736(12)61422-6
Jindal A., Gupta M., Sharma G. et al. Comparative evaluation of voglibose versus pioglitazone on glycaemic control and lipid profile in patients of type 2 diabetes mellitus on glimepiride and metformin in punjabi population // Int. J. Basic Clin. Pharmacol. — 2012. — Vol. 1(3). — P. 160-167. doi: 10.5455/2319-2003.ijbcp002412
Roberts V.L., Stewart J., Issa M. et al. Triple drug therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione // Clin. Ther. — 2005. — Vol. 27. — P. 1535-47. http://dx.doi.org/10.1016/j.clinthera.2005.10.017
Derosa G., Salvedeo S.A., D’Angelo A. et al. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double blind, cross over, clinical trial // Curr. Med. Res Opin. — 2009. — Vol. 25. — P. 607-615. http://dx.doi.org/10.1185/03007990802711024
Iwamoto Y., Kashiwagi A., Yamada N. et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes; a 12 week, randomized, double blind, active controlled study // Diabetes Obes Metab. — 2010. — Vol. 12. — P. 700-708. http://dx.doi.org/10.1111/j.1463-1326.2010.01222.x
Van de Laar F.A., Lucassen P.L., Akkermans R.P. et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus // Cochrane Database Syst Rev. — 2005. — Apr 18. — (2). CD003639.